| MTX-naive | MTX-user | ||||||
|---|---|---|---|---|---|---|---|
| Victims | Non-victims | ASD | Victims | Non-victims | ASD | ||
| All participants, n | 31,006 | 4,942,395 | 110 | 14,798 | |||
| Age classification, n (%) | 20-44 | 6,668 (21.5%) | 1,710,176 (34.6%) | 0.295 | a (a) | 1,067 (7.2%) | NC |
| 45-64 | 8,103 (26.1%) | 1,451,712 (29.4%) | 0.074 | b (b) | 4,949 (33.4%) | NC | |
| 65+ | 16,235 (52.4%) | 1,780,507 (36.0%) | 0.335 | 74 (67.3%) | 8,782 (59.3%) | NC | |
| Sex, n (%) | Male | 13,528 (43.6%) | 2,298,159 (46.5%) | 0.058 | 31 (28.2%) | 3,948 (26.7%) | 0.034 |
| Female | 17,478 (56.4%) | 2,644,236 (53.5%) | 0.058 | 79 (71.8%) | 10,850 (73.3%) | 0.034 | |
| Victims | Non-victims | p-Value | |
|---|---|---|---|
| MTX, n (%) | 54 (0.17%) | 3,811 (0.08%) | p < 0.001 |
| bDMARDs, n (%) | a (a) | 414 (2.8%) | p = 0.093 |
| csDMARDs. n (%) | a (a) | 1,074 (7.3%) | p = 0.467 |
| Glucocorticoid, n (%) | 13 (11.8%) | 1,547 (10,5%) | p = 0.641 |
| Any of the antirheumatic drugs | 23 (20.9%) | 2,627 (17.8%) | p = 0.388 |